Sponsored

Maria Pia Morelli, MD, PhD, assistant professor, MD Anderson Cancer Center, discussed her work on the EVEREST-1 trial of logic-gated CAR T-cell therapy currently being evaluated in colorectal and pancreatic cancers.

The medical oncologist at Moffitt Cancer Center spoke about A2 Bio’s A2B530 as part of a larger discussion of novel cell therapy approaches in solid tumors.

Ben Creelan, MD, a medical oncologist at Moffitt Cancer Center, discussed several different approaches to cell therapy that could lead to new treatment options in the field.

The assistant professor at MD Anderson Cancer Center discussed the EVEREST-1 clinical trial of A2B530.

J. Randolph Hecht, MD, discusses the challenges researchers have faced in the development of cellular therapy for patients with solid tumors, and details how A2B530 could potentially overcome some of these obstacles.

The assistant member in the Department of Head and Neck-Endocrine Oncology at Moffitt Cancer Center spoke about A2B530's mechanism of action and how it could represent a leap forward in the application of CAR T-cell agents for patients with solid tumors.

Marwan G. Fakih, MD, discusses how the BASECAMP-1 and EVEREST-1 trials will work in concert, diving into the unique mechanism of action of A2B530.

The BASECAMP-1 clinical trial will aim to find patients with advanced solid tumors who are good candidates for the subsequent EVEREST trial.

The autologous CAR T-cell therapy A2B530 is being investigated for solid tumors in the multicenter, first-in-human, phase 1/2 EVEREST-1 study.

Diane M. Simeone, MD, discussed the phase 1/2 EVEREST-1 trial, which seeks to assess the novel CAR T-cell therapy A2B530 in patients with solid tumors—hopefully progressing one-and-done engineered therapies in this population.

Investigators have initiated the BASECAMP-1 trial of investigational agent A2B530 with the hope of identifying patients with advanced solid tumors who will be suitable candidates for treatment in a subsequent trial.